No Data
Nhwa Pharma's Opioids Gets China Drug Trial Approval
Jiangsu NHWA Pharmaceutical (002262.SZ): Type 1 chemical drug NH160030 tablets approved for clinical trials.
Gelonghui November 12th | Jiangsu NHWA Pharmaceutical (002262.SZ) announced that the company recently received the approval and issuance of a Type 1 chemical drug NH160030 tablet with 4 specifications by the National Medical Products Administration (hereinafter referred to as the "NMPA"), and will conduct clinical trials in the near future. NH160030 is an orally biased μ-opioid receptor agonist, a new generation of opioid analgesics. Preclinical trial results show that compared to commonly used opioid analgesics such as morphine and hydrocodone, it has superior efficacy and fewer side effects. NH160030 is derived from internal research.
Nhwa Pharmaceutical's Unit Gets Nod for Diquafosol Sodium Eye Drops' Registration
Jiangsu NHWA Pharmaceutical (002262.SZ): Yuanheng Pharmaceutical obtains the pharmaceutical registration certificate of Diquafosol Sodium Eye Drops.
Jiangsu NHWA Pharmaceutical (002262.SZ) announced on November 5th that its subsidiary Jiangsu Yuanheng Pharmaceutical Co., Ltd. (hereinafter referred to as Yuanheng Pharmaceutical) recently obtained the "Drug Registration Certificate" for the chemical drug diquasodium toluidine eye drops issued by the National Medical Products Administration. Diquasodium toluidine eye drops are suitable for dry eye patients diagnosed with corneal epithelial damage accompanied by abnormal tear fluid. By acting on the conjunctival tissue and P2Y2 receptors on the cup-shaped cell membrane, it increases intracellular calcium ion concentration, promotes the secretion of tear fluid containing water and mucin, and brings the tear film layer closer to a normal state in terms of quality and quantity.
Enhua Pharmaceutical: Report for the third quarter of 2024
jiangsu nhwa pharmaceutical (002262.SZ): net income of 1.02 billion yuan in the first three quarters, a year-on-year increase of 15.18%.
Gelonghui Oct. 25th | Jiangsu NHWA Pharmaceutical (002262.SZ) announced the third quarter report for 2024, achieving revenue of 4.145 billion yuan in the first three quarters, a year-on-year increase of 13.39%; net income attributable to shareholders of the listed company was 1.02 billion yuan, an increase of 15.18% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.03 billion yuan, an increase of 16.35% year-on-year; basic earnings per share of 1.01 yuan.
Little Excitement Around Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) EarningsNo Data
No Data
